Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.45 |
| ▸ | CA2 | P00918 | 7/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9678442 | 0.84 | LMNA (0.46) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL1809268 | 0.83 | ALDH1A1 (0.58) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL5171496 | 0.82 | ALDH1A1 (0.56) | LMNAMAPTCA1CA2MAPK1 | |
| Hydrochloric Acid SCHEMBL1726778 | 0.82 | ALDH1A1 (0.56) | LMNAMAPTCA1CA2MAPK1 | |
| SCHEMBL57630 | 0.82 | LMNA (0.62) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL29609090 | 0.81 | LMNA (0.52) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL18281078 | 0.81 | LMNA (0.68) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL1670578 | 0.81 | LMNA (0.54) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL716770 | 0.81 | LMNA (0.54) | LMNAMAPTCA1CA2CYP1A2 | |
| SCHEMBL719791 | 0.81 | LMNA (0.54) | LMNAMAPTCA1CA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1544208-B1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7655632-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20080312153-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7375087-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1544208-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0895988-B1 | Arylsulfonylamino hydroxamic acid derivatives | PFIZER PROD INC (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6214872-B1 | ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS | PFIZER INC. | 2001-04-10 | — | — | US | disclosed |
| US-6107337-A | ANTIARTHRITIC AGENTS; ANTICARCINOGENIC AGENTS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-1003720-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999007675-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0895988-A1 | Arylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 1999-02-10 | — | — | EP | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0333000-B1 | PEPTIDES WITH INHIBITORY ACTIVITY OF ENZYMATIC SYSTEMS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZAMBON GROUP S.p.A. (IT) | 1993-05-19 | — | — | EP | disclosed |
| US-5145872-A | PEPTIDES WITH PHARMACEUTICAL ACTIVITY | ZAMBON GROUP, S.P.A. (IT) | 1992-09-08 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | SLC5A1, SLC5A2, SULT2A1 | LMNA 4724/4885MAPT 2068/4885CA1 3021/4885 |
| US-20080312153-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | SLC5A1, SLC5A2, SULT2A1 | LMNA 4724/4885MAPT 2068/4885CA1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.